<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="66998">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01732939</url>
  </required_header>
  <id_info>
    <org_study_id>307BCNeo-01</org_study_id>
    <nct_id>NCT01732939</nct_id>
  </id_info>
  <brief_title>Phase II Study of Neoadjuvant Chemotherapy Regimen Choice in Breast Cancer</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Affiliated to Military Medical Science, Beijing</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Affiliated to Military Medical Science, Beijing</source>
  <oversight_info>
    <authority>China: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study purpose is to observe which neoadjuvant chemotherapy regimens is the better for
      invasive breast cancer. The neoadjuvant chemotherapy regimen is sustained anthracyclines
      plus taxanes or from anthracyclines plus taxanes to vinorelbine plus cisplatinum.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators hope to get preliminary results for the breast cancer patients who are
      given different neoadjuvant chemothetapy regimens. The patients are randomized two
      chemotherapy regimens. One is anthracyclines plus taxanes for 6-8 cycles,the other is
      anthracyclines plus taxanes for 3-4 cycles ,then switch tovinorelbine plus cisplatinum for
      3-4 cycles.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Anticipated">May 2014</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>pathological complete response rate</measure>
    <time_frame>one year</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>clinical response rate, safety</measure>
    <time_frame>one year</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>AT</arm_group_label>
    <description>Docetaxel 75 mg/m2, day 1 or paclitaxel 175mg/m2 day 1 plus Epirubicin 75 mg/m2, day 1 or doxorubicine 50mg/m2 day 1 for 6-8 cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AT-NP</arm_group_label>
    <description>docetaxel 75mg/m2,day 1 or paclitaxel 175mg/m2,day 1 plus doxorubicine 50mg/m2,day 1 or epirubicin 75mg/m2, day 1,for3-4 cycles then switch to  vinorelbine 25mg/m2, day 1 and day 8 plus cisplatinum 75mg/m2, day 1 for 3-4 cycles</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        diaganosis of invasive breast cancer, tumor size &gt; 2.0cm by MRI or ultrasound or clinical
        examination.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of invasive ductal or lobular breast cancer.

          -  Previously untreated (no chemotherapy or hormonal therapy or radiation therapy)
             invasive breast cancer.

          -  no anti-Her2 therapy if HER2 positive ( defined as 3+ IHC or FISH positive)

          -  Performance Status ECOG &lt;2

          -  Age &gt; 18 years

          -  Tumor &gt; 2.0 cm by MRI and/or sonographic or clinical exam measurements.or Karnofsky
             &gt;50%

          -  Lab test :

               -  Absolute neutrophil count &gt; 1,500/mm3

                    -  Total Bilirubin ≤ 2×ULN

                    -  AST and ALT ≤ 2.5×ULN

               -  serum creatinine ≤ 1.5×ULN

        Exclusion Criteria:

          -  Pregnant or breast feeding patients are excluded

          -  stage Ⅳ breast cancer

          -  History of non-breast malignancies within the 5 years prior to study entry, except
             for the following: carcinoma in situ of the cervix, carcinoma in situ of the
             colon,melanoma in situ, and basal cell and squamous cell carcinomas of the skin

          -  uncontrolled cardiac disease

          -  Active infection or chronic infection requiring chronic suppressive antibiotics

          -  History of hypersensitivity reaction to investigating drugs
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zefei Jiang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Affiliated Military Medical Science</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital affiliated academy military medical science</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100071</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tao Wang, MD</last_name>
      <phone>8610-66947430</phone>
    </contact>
    <contact_backup>
      <last_name>Shaohua ZHANG, MD</last_name>
      <phone>8610-66947173</phone>
    </contact_backup>
    <investigator>
      <last_name>Zefei Jiang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 17, 2014</lastchanged_date>
  <firstreceived_date>October 10, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
